Elicio Therapeutics, Inc. (ELTX) — SEC Filings
Elicio Therapeutics, Inc. (ELTX) — 42 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 26 8-K, 6 10-Q, 5 SC 13D/A.
View Elicio Therapeutics, Inc. on SEC EDGAR
Overview
Elicio Therapeutics, Inc. (ELTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Elicio Therapeutics, Inc. (ELTX) reported a net loss of $10.083 million for the three months ended September 30, 2025, a significant improvement from the $18.838 million loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $31.853 million, down from $37.894
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 1 bearish, 40 neutral, 1 mixed. The dominant filing sentiment for Elicio Therapeutics, Inc. is neutral.
Filing Type Overview
Elicio Therapeutics, Inc. (ELTX) has filed 6 10-Q, 26 8-K, 2 DEF 14A, 2 10-K, 5 SC 13D/A, 1 10-K/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of ELTX's 34 recent filings, 2 were flagged as high-risk, 21 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$10.083M |
| EPS | N/A |
| Debt-to-Equity | 2.54 |
| Cash Position | $20.611M |
| Operating Margin | N/A |
| Total Assets | $28.284M |
| Total Debt | $9.720M |
Key Executives
- Dr. Jonathan G. Drachman
- Ms. Sarah E. Kelly
- Dr. Robert L. R. Burns
- Dr. David J. Apelian
- Dr. Jonathan M. Rothberg
- Len Blavatnik
- Alejandro Moreno
- Langhorne S. Perrow
Industry Context
Elicio Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel immunotherapies. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often depends on groundbreaking scientific innovation, effective clinical trial execution, and securing substantial funding to navigate these challenges.
Top Tags
corporate-governance (6) · 8-K (5) · ownership-change (5) · sec-filing (5) · material-definitive-agreement (4) · corporate-filing (3) · company-update (3) · SEC Filing (3) · 10-Q (3) · equity-sale (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $10.083M | Improved from $18.838M in Q3 2024, indicating reduced operational burn. |
| Cash & Cash Equivalents | $20.611M | Increased from $17.618M at Dec 31, 2024, providing a longer cash runway. |
| R&D Expenses (9M 2025) | $19.823M | Decreased from $22.947M in 9M 2024, reflecting a more focused or reduced research spend. |
| Total Liabilities | $24.468M | Significantly reduced from $39.490M at Dec 31, 2024, primarily due to debt conversion. |
| Accumulated Deficit | $225.954M | Increased from $194.101M at Dec 31, 2024, highlighting ongoing losses and the need for future funding. |
| Common Shares Outstanding | 17,489,516 | As of November 10, 2025, reflecting dilution from recent equity offerings. |
| Senior Note Conversion | $20.176M | Amount converted into common stock, reducing debt and increasing equity. |
| ATM Offering Proceeds | $11.385M | Net proceeds from at-the-market offerings, contributing to cash increase. |
| SEC File Number | 001-39990 | Identifies the company's filing history |
| IRS Employer Identification No. | 11-3430072 | Tax identification for the company |
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating pre-commercial stage |
| Conformed Period of Report | 2025-06-30 | the end date of the financial period covered by the 10-Q |
| Filed As Of Date | 2025-08-07 | the date the 10-Q was officially filed |
| Standard Industrial Classification (SIC) | 2834 | Pharmaceutical Preparations, defining the company's industry |
| Period End Date | 20250331 | The filing covers the financial period ending March 31, 2025. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Elicio Therapeutics, Inc. (ELTX)?
Elicio Therapeutics, Inc. has 42 recent SEC filings from Jan 2024 to Nov 2025, including 26 8-K, 6 10-Q, 5 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ELTX filings?
Across 42 filings, the sentiment breakdown is: 1 bearish, 40 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Elicio Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Elicio Therapeutics, Inc. (ELTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Elicio Therapeutics, Inc.?
Key financial highlights from Elicio Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ELTX?
The investment thesis for ELTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Elicio Therapeutics, Inc.?
Key executives identified across Elicio Therapeutics, Inc.'s filings include Dr. Jonathan G. Drachman, Ms. Sarah E. Kelly, Dr. Robert L. R. Burns, Dr. David J. Apelian, Dr. Jonathan M. Rothberg and 3 others.
What are the main risk factors for Elicio Therapeutics, Inc. stock?
Of ELTX's 34 assessed filings, 2 were flagged high-risk, 21 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Elicio Therapeutics, Inc.?
Forward guidance and predictions for Elicio Therapeutics, Inc. are extracted from SEC filings as they are enriched.